Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.

Hasugian AR, Tjitra E, Ratcliff A, Siswantoro H, Kenangalem E, Wuwung RM, Purba HL, Piera KA, Chalfien F, Marfurt J, Penttinen PM, Russell B, Anstey NM, Price RN.

Antimicrob Agents Chemother. 2009 Mar;53(3):1094-9. doi: 10.1128/AAC.01511-08. Epub 2008 Dec 22.

2.

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E.

Antimicrob Agents Chemother. 2007 Nov;51(11):4090-7. Epub 2007 Sep 10.

3.

Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.

Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN.

Clin Infect Dis. 2007 Apr 15;44(8):1067-74. Epub 2007 Mar 5.

Supplemental Content

Loading ...
Support Center